> top > docs > PubMed:7914731 > annotations

PubMed:7914731 JSONTXT

Annnotations TAB JSON ListView MergeView

jnlpba-st-training

Id Subject Object Predicate Lexical cue
T1 56-68 cell_type denotes tumour cells
T2 123-126 protein denotes CD4
T3 253-265 cell_type denotes tumour cells
T4 332-336 protein denotes CD4+
T5 390-431 protein denotes anti-Z Epstein-Barr replicative activator
T6 433-438 protein denotes ZEBRA
T7 441-459 protein denotes anti-early antigen
T8 461-463 protein denotes EA
T9 466-491 protein denotes anti-viral capsid antigen
T10 493-496 protein denotes VCA
T11 695-699 protein denotes CD4+
T12 756-761 protein denotes ZEBRA
T13 975-985 protein denotes anti-ZEBRA
T14 987-1026 protein denotes anti-EA-restricted, anti-VCA antibodies
T15 1152-1156 protein denotes CD4+
T16 1337-1362 protein denotes recombinant ZEBRA protein
T17 1389-1397 protein denotes antigens
T18 1408-1413 protein denotes BZLF1
T19 1415-1420 protein denotes ZEBRA
T20 1425-1444 protein denotes early gene products
T21 1446-1450 protein denotes EA-R
T22 1455-1470 protein denotes EA-D/BHLF1/NotI
T23 1523-1535 cell_type denotes tumour cells
T24 1693-1697 protein denotes CD4+
T25 1766-1771 protein denotes ZEBRA
T26 2012-2024 cell_type denotes tumour cells
T27 2064-2069 protein denotes ZEBRA

genia-medco-coref

Id Subject Object Predicate Lexical cue
C2 72-107 NP denotes AIDS-related non-Hodgkin's lymphoma
C1 0-107 NP denotes Epstein-Barr virus (EBV) replicative gene expression in tumour cells of AIDS-related non-Hodgkin's lymphoma
C3 123-138 NP denotes CD4 cell number
C4 143-165 NP denotes antibody titres to EBV
C6 269-312 NP denotes AIDS-related non-Hodgkin's lymphoma (ARNHL)
C5 213-312 NP denotes Epstein-Barr virus (EBV) replication in tumour cells of AIDS-related non-Hodgkin's lymphoma (ARNHL)
C7 332-348 NP denotes CD4+ cell counts
C9 389-498 NP denotes [anti-Z Epstein-Barr replicative activator (ZEBRA), anti-early antigen (EA), anti-viral capsid antigen (VCA)]
C8 364-498 NP denotes antibody response to EBV [anti-Z Epstein-Barr replicative activator (ZEBRA), anti-early antigen (EA), anti-viral capsid antigen (VCA)]
C10 537-557 NP denotes immunohistochemistry
C11 562-583 NP denotes in situ hybridization
C12 594-623 NP denotes EBV replicative gene products
C14 668-673 NP denotes ARNHL
C13 647-673 NP denotes patients affected by ARNHL
C15 695-711 NP denotes CD4+ cell counts
C16 727-739 NP denotes EBV serology
C17 751-770 NP denotes anti-ZEBRA activity
C18 785-802 NP denotes the same patients
C20 842-847 NP denotes ARNHL
C19 813-847 NP denotes Seventeen out of 22 cases of ARNHL
C21 935-955 NP denotes Immunohistochemistry
C22 975-1026 NP denotes anti-ZEBRA, anti-EA-restricted, anti-VCA antibodies
C23 1031-1052 NP denotes in situ hybridization
C24 1100-1107 NP denotes Results
C25 1143-1148 NP denotes those
C26 1152-1168 NP denotes CD4+ cell counts
C27 1193-1217 NP denotes anti-EBV antibody titres
C28 1523-1535 NP denotes tumour cells
C29 1548-1562 NP denotes these 17 cases
C30 1566-1586 NP denotes immunohistochemistry
C31 1591-1612 NP denotes in situ hybridization
C32 1631-1658 NP denotes replicative gene expression
C33 1724-1748 NP denotes anti-EBV antibody titres
C34 1761-1780 NP denotes Anti-ZEBRA activity
C36 1839-1844 NP denotes ARNHL
C35 1816-1844 NP denotes patients affected with ARNHL
C37 1846-1855 NP denotes the cells
C38 1859-1864 NP denotes which
C39 1875-1900 NP denotes replicative gene products
C40 1981-2008 NP denotes replicative gene expression
C41 2012-2024 NP denotes tumour cells
C42 2028-2033 NP denotes ARNHL
C43 2035-2047 NP denotes EBV serology
R1 C6 C2 coref-ident AIDS-related non-Hodgkin's lymphoma (ARNHL),AIDS-related non-Hodgkin's lymphoma
R2 C5 C1 coref-ident Epstein-Barr virus (EBV) replication in tumour cells of AIDS-related non-Hodgkin's lymphoma (ARNHL),Epstein-Barr virus (EBV) replicative gene expression in tumour cells of AIDS-related non-Hodgkin's lymphoma
R3 C7 C3 coref-ident CD4+ cell counts,CD4 cell number
R4 C8 C4 coref-ident "antibody response to EBV [anti-Z Epstein-Barr replicative activator (ZEBRA), anti-early antigen (EA), anti-viral capsid antigen (VCA)]",antibody titres to EBV
R5 C14 C6 coref-ident ARNHL,AIDS-related non-Hodgkin's lymphoma (ARNHL)
R6 C15 C7 coref-ident CD4+ cell counts,CD4+ cell counts
R7 C18 C13 coref-ident the same patients,patients affected by ARNHL
R8 C20 C14 coref-ident ARNHL,ARNHL
R9 C21 C10 coref-ident Immunohistochemistry,immunohistochemistry
R10 C22 C9 coref-ident "anti-ZEBRA, anti-EA-restricted, anti-VCA antibodies","[anti-Z Epstein-Barr replicative activator (ZEBRA), anti-early antigen (EA), anti-viral capsid antigen (VCA)]"
R11 C23 C11 coref-ident in situ hybridization,in situ hybridization
R12 C25 C24 coref-pron those,Results
R13 C26 C15 coref-ident CD4+ cell counts,CD4+ cell counts
R14 C27 C4 coref-ident anti-EBV antibody titres,antibody titres to EBV
R15 C29 C19 coref-ident these 17 cases,Seventeen out of 22 cases of ARNHL
R16 C30 C21 coref-ident immunohistochemistry,Immunohistochemistry
R17 C31 C23 coref-ident in situ hybridization,in situ hybridization
R18 C33 C27 coref-ident anti-EBV antibody titres,anti-EBV antibody titres
R19 C34 C17 coref-ident Anti-ZEBRA activity,anti-ZEBRA activity
R20 C36 C20 coref-ident ARNHL,ARNHL
R21 C35 C18 coref-ident patients affected with ARNHL,the same patients
R22 C38 C37 coref-relat which,the cells
R23 C39 C12 coref-ident replicative gene products,EBV replicative gene products
R24 C40 C32 coref-ident replicative gene expression,replicative gene expression
R25 C41 C28 coref-ident tumour cells,tumour cells
R26 C42 C36 coref-ident ARNHL,ARNHL
R27 C43 C16 coref-ident EBV serology,EBV serology

pubmed-sentences-benchmark

Id Subject Object Predicate Lexical cue
S1 0-166 Sentence denotes Epstein-Barr virus (EBV) replicative gene expression in tumour cells of AIDS-related non-Hodgkin's lymphoma in relation to CD4 cell number and antibody titres to EBV.
S2 167-499 Sentence denotes OBJECTIVE: To determine whether activation of Epstein-Barr virus (EBV) replication in tumour cells of AIDS-related non-Hodgkin's lymphoma (ARNHL) is correlated with CD4+ cell counts and influences antibody response to EBV [anti-Z Epstein-Barr replicative activator (ZEBRA), anti-early antigen (EA), anti-viral capsid antigen (VCA)].
S3 500-803 Sentence denotes DESIGN: Retrospective study based on immunohistochemistry and in situ hybridization to detect EBV replicative gene products in tissue samples from patients affected by ARNHL and correlation with CD4+ cell counts and results of EBV serology (including anti-ZEBRA activity) in sera from the same patients.
S4 804-934 Sentence denotes METHODS: Seventeen out of 22 cases of ARNHL were selected for the presence of EBV [Epstein-Barr early region (EBER) RNA-positive].
S5 935-1099 Sentence denotes Immunohistochemistry was performed with anti-ZEBRA, anti-EA-restricted, anti-VCA antibodies and in situ hybridization with BHLF1/NotI oligoprobes on tumour samples.
S6 1100-1398 Sentence denotes Results were statistically correlated with those of CD4+ cell counts (17 out of 17) and with anti-EBV antibody titres (13 out of 17) assessed using standard immunofluorescence method and enzyme-linked immunosorbent assay procedure using recombinant ZEBRA protein and synthetic peptides as antigens.
S7 1399-1613 Sentence denotes RESULTS: BZLF1 (ZEBRA) or early gene products (EA-R and EA-D/BHLF1/NotI) were detected in a small proportion (< 0.01-5%) of tumour cells in eight of these 17 cases by immunohistochemistry and in situ hybridization.
S8 1614-1760 Sentence denotes Demonstration of replicative gene expression did not correlate with either low CD4+ cell counts (P > 0.05) or anti-EBV antibody titres (P > 0.05).
S9 1761-1912 Sentence denotes Anti-ZEBRA activity was not significantly increased in patients affected with ARNHL, the cells of which expressed replicative gene products (P > 0.05).
S10 1913-2034 Sentence denotes CONCLUSION: The degree of immunodeficiency does not clearly enhance replicative gene expression in tumour cells of ARNHL.
S11 2035-2156 Sentence denotes EBV serology, including anti-ZEBRA activity, is not a reliable tool for predicting the occurrence of such proliferations.

GENIAcorpus

Id Subject Object Predicate Lexical cue
T1 0-18 virus denotes Epstein-Barr virus
T2 20-23 virus denotes EBV
T3 56-68 cell_type denotes tumour cells
T4 72-107 other_name denotes AIDS-related non-Hodgkin's lymphoma
T5 123-126 protein_molecule denotes CD4
T6 143-158 other_name denotes antibody titres
T7 162-165 virus denotes EBV
T8 213-231 virus denotes Epstein-Barr virus
T9 233-236 virus denotes EBV
T10 253-265 cell_type denotes tumour cells
T11 269-304 other_name denotes AIDS-related non-Hodgkin's lymphoma
T12 306-311 other_name denotes ARNHL
T13 332-336 protein_molecule denotes CD4+
T14 385-388 virus denotes EBV
T15 390-431 protein_molecule denotes anti-Z Epstein-Barr replicative activator
T16 433-438 protein_molecule denotes ZEBRA
T17 441-459 protein_family_or_group denotes anti-early antigen
T18 461-463 protein_family_or_group denotes EA
T19 466-491 protein_family_or_group denotes anti-viral capsid antigen
T20 493-496 protein_family_or_group denotes VCA
T21 537-557 other_name denotes immunohistochemistry
T22 594-597 virus denotes EBV
T23 647-655 multi_cell denotes patients
T24 668-673 other_name denotes ARNHL
T25 695-699 protein_molecule denotes CD4+
T26 727-730 virus denotes EBV
T27 751-756 other_name denotes anti-
T28 756-761 protein_molecule denotes ZEBRA
T29 775-779 tissue denotes sera
T30 794-802 multi_cell denotes patients
T31 842-847 other_name denotes ARNHL
T32 882-885 virus denotes EBV
T33 887-932 other_name denotes Epstein-Barr early region (EBER) RNA-positive
T34 935-955 other_name denotes Immunohistochemistry
T35 975-980 protein_family_or_group denotes anti-
T36 980-985 protein_molecule denotes ZEBRA
T37 987-992 protein_family_or_group denotes anti-
T38 992-994 protein_family_or_group denotes EA
T39 1012-1015 protein_family_or_group denotes VCA
T40 1031-1052 other_name denotes in situ hybridization
T41 1058-1080 polynucleotide denotes BHLF1/NotI oligoprobes
T42 1084-1098 tissue denotes tumour samples
T43 1152-1156 protein_molecule denotes CD4+
T44 1198-1201 virus denotes EBV
T45 1248-1282 other_name denotes standard immunofluorescence method
T46 1287-1330 other_name denotes enzyme-linked immunosorbent assay procedure
T47 1337-1348 protein_family_or_group denotes recombinant
T48 1349-1354 protein_molecule denotes ZEBRA
T49 1367-1385 peptide denotes synthetic peptides
T50 1389-1397 protein_family_or_group denotes antigens
T51 1408-1413 protein_molecule denotes BZLF1
T52 1415-1420 protein_molecule denotes ZEBRA
T53 1425-1444 protein_family_or_group denotes early gene products
T54 1446-1450 protein_molecule denotes EA-R
T55 1455-1470 protein_molecule denotes EA-D/BHLF1/NotI
T56 1523-1535 cell_type denotes tumour cells
T57 1566-1586 other_name denotes immunohistochemistry
T58 1591-1612 other_name denotes in situ hybridization
T59 1643-1658 other_name denotes gene expression
T60 1693-1697 protein_molecule denotes CD4+
T61 1724-1729 other_name denotes anti-
T62 1729-1732 virus denotes EBV
T63 1761-1766 other_name denotes Anti-
T64 1766-1771 protein_molecule denotes ZEBRA
T65 1816-1824 multi_cell denotes patients
T66 1839-1844 other_name denotes ARNHL
T67 1939-1955 other_name denotes immunodeficiency
T68 1993-2008 other_name denotes gene expression
T69 2012-2024 cell_type denotes tumour cells
T70 2028-2033 other_name denotes ARNHL
T71 2035-2038 virus denotes EBV
T72 2059-2064 other_name denotes anti-
T73 2064-2069 protein_molecule denotes ZEBRA